Kottil W. Rammohan
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
Neuroscience Biology, Molecular Biology, ImmunologyGoogle:
"Kottil Rammohan"Mean distance: 106866
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Vermersch P, Giovannoni G, Sørensen PS, et al. (2020) Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study Multiple Sclerosis and Related Disorders. 37: 101602 |
Giovannoni G, Soelberg Sorensen P, Cook S, et al. (2017) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517727603 |
Giovannoni G, Rammohan K, Cook S, et al. (2017) PO138 High disease activity in relapsing multiple sclerosis (rms) Journal of Neurology, Neurosurgery, and Psychiatry. 88 |
Hadjixenofontos A, Beecham AH, Manrique CP, et al. (2015) Clinical Expression of Multiple Sclerosis in Hispanic Whites of Primarily Caribbean Ancestry. Neuroepidemiology. 44: 262-8 |
Delgado SR, Lavi ES, Campos YA, et al. (2014) Natalizumab Associated PML in a Multiple Sclerosis Patient: Excellent Response to Minimal Intervention Journal of Multiple Sclerosis. 1: 1-4 |
Rammohan K, Giovannoni G, Comi G, et al. (2012) Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders. 1: 49-54 |
Ortega MR, Usmani N, Parra-Herran C, et al. (2012) CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma. Neurology. 79: 715-6 |
Rammohan KW, Ortega MR, Delgado SR, et al. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 77: 1930; discussion 193 |
Giovannoni G, Cook S, Rammohan K, et al. (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis Lancet Neurology. 10: 329-337 |
Giovannoni G, Comi G, Cook S, et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England Journal of Medicine. 362: 416-26 |